‘Generic Drugs Market Worth $384.0bn In 2021’ Says Visiongain Report

29 August 2018
Pharma

Visiongain’s new report Generic Drugs Market Forecast 2017-2027: Growth in Leading Regional and National Markets – US, EU5, Asia-Pacific, Emerging Markets indicates that the generic drugs market will see $384.0bn in spending in 2021.

The generic drugs market is expected to grow at a CAGR of 8.8% in the first half of the forecast period and CAGR of 7.0% in the second half of the forecast period. The market is expected to grow at a CAGR of 7.9% from 2015 to 2027. The market is estimated at $254.6bn in 2016, $384.0bn in 2021, and $574.7bn in 2027.

The lead analyst of the report said: “The global generics market is assured of good growth rates and high revenues. Drivers in this market include the continual assistance of governments in promoting the use of generics as a mean to cut healthcare costs and the perpetual loss of patents of high earning branded pharmaceuticals. Other drivers include an increase in the ageing population who are most likely to become ill and will therefore demand cheap and effective drugs, generic or otherwise. However, a major concern to generic companies has to be the high level of competition within this market which will inevitably lead to lower prices and overall profitability. A general trend in response to this will be a higher level of merger and acquisitions between generic companies.

In a further response to this competition there will be an increasingly number of generic companies who will be investing in the production of their own branded patentable drugs. However, the future of the generics market, whatever form it takes, will continue to be lucrative and very attractive“

The 303 page report contains 89 tables and 87 charts that add visual analysis in order to explain the developing trends within the Generic Drugs Market. Visiongain provides revenue forecasts for the period 2017-2027.

The 303 page report offers market forecasts and analysis for 14 leading national markets: US, Japan, Germany, UK, France, Spain, Italy, Brazil, Russia, China, India, South Korea, Mexico and Turkey. In addition, the report contains a dedicated leading companies’ chapter covering companies leading the field in the generic drugs market.

The Generic Drugs Market Forecast 2017-2027: Growth in Leading Regional and National Markets – US, EU5, Asia-Pacific, Emerging Markets report will be of value to anyone who wants to better understand the Generic Drugs market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the Generic Drugs industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Next-Generation Pharmaceutical Temperature Management Solutions Market Report 2020-2030

Maintaining the quality and safety of the product in the supply chain has always been a high priority for pharmaceutical companies. New market dynamics including an evolving product line, more stringent regulations, geographically connected supply chains, rising risk, and extreme cost pressure have raised stakes significantly.

28 September 2020

Read

Visiongain Publishes OTC Drugs & Dietary Supplements Market Report 2020-2030

The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.

23 September 2020

Read

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

Read

Visiongain Publishes Vaccines Sales Market Report 2020-2030

Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.

14 September 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever